Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

NMDA antagonists claimed by E. Merck

Aug. 9, 1996

Dainippon's new compound superior to metoclopramide for digestive function improvement

Aug. 9, 1996

Teva's Copaxone progresses toward FDA approval

Aug. 9, 1996

5-HT1A agonist with alpha1-adrenoceptor-blocking properties from Byk Gulden

Aug. 9, 1996

Multiuse melatonergic 3-alkoxybenzylpiperidine derivatives from Bristol-Myers Squibb

Aug. 9, 1996

ADIR describes compunds with high affinity for 5-HT2C and/or 5-HT3C receptors

Aug. 9, 1996

Lidocaine nasal drops shown effective for fast migraine pain relief

Aug. 9, 1996

5-HT1 agonists described by Merck & Co.

Aug. 9, 1996

Actiq to undergo phase III clinical trials

Aug. 9, 1996

Menarini and Lilly sign comarketing agreement

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...